22
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Patient Preference and Adherence (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the growing importance of patient preference and adherence throughout the therapeutic process. Sign up for email alerts here.

      34,896 Monthly downloads/views I 2.314 Impact Factor I 3.8 CiteScore I 1.14 Source Normalized Impact per Paper (SNIP) I 0.629 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Perception of stigma was associated with low self-esteem, psychological problems, and decreased health-seeking behavior among patients with different neurological disorders. The purpose of this study was to assess stigmatization and its impact in patients with neuromyelitis optica spectrum disorder (NMOSD).

          Methods

          A non-interventional study was conducted at thirteen neuroimmunology clinics in Spain. Patients with a diagnosis of NMOSD (2015 Wingerchuk criteria) were included. The 8-item Stigma Scale for Chronic Illness (SSCI-8), the Expanded Disability Status Scale (EDSS), the 29-item Multiple Sclerosis Impact Scale (MSIS-29), the Beck Depression Inventory-Fast Screen (BDI-FS), the MOS Pain Effects Scale (MOS-PES) and the Fatigue Impact Scale for Daily Use (D-FIS) were used to assess the perception of stigma, disability, quality of life, mood, pain, and fatigue, respectively. Associations between outcome measures were analyzed using Spearman’s rank correlation.

          Results

          Seventy-one patients were studied (mean age: 47.4 years ± 14.9, 81.7% female, mean time since disease onset: 9.9 years ± 8.1). The median EDSS score was 3.0 (interquartile range 1.5, 4.5). Stigma prevalence was 61.4% (n=43). Thirty-one patients (43.6%) had depression. The SSCI-8 score showed a significant correlation with both physical (rho=0.576, p<0.0001) and psychological (rho=0.608, p<0.0001) MSIS-29 scales scores, EDSS score (rho=0.349, p=0.0033), BDI-FS score (rho= 0.613, p<0.0001), MOS-PES score (rho= 0.457, p<0.0001), and D-FIS score (rho=0.556, p<0.0001).

          Conclusion

          Stigma is a common phenomenon affecting over 6 out of 10 patients with NMOSD. Understanding stigma may be useful to develop educational strategies improving NMOSD knowledge.

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

          J. Kurtzke (1983)
          One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

            Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.

              J. Höbart (2001)
              Changes in health policy have underlined the importance of evidence-based clinical practice and rigorous evaluation of patient-based outcomes. As patient-based outcome measurement is particularly important in treatment trials of multiple sclerosis, a number of disease-specific instruments have been developed recently. One limitation of these instruments is that none was developed using the standard psychometric approach of reducing a large item pool generated from people with multiple sclerosis. Consequently, an outcome measure for clinical trials of multiple sclerosis that is disease specific and combines patient perspective with rigorous psychometric methods will complement existing instruments. The aim of this study was to develop such a measure. Standard psychometric methods were used. A pool of 129 questionnaire items was generated from interviews with 30 people with multiple sclerosis, expert opinion and literature review. The questionnaire was administered by postal survey to 1530 people selected randomly from the Multiple Sclerosis Society membership database. Redundant items and those with limited measurement properties were removed. The remaining items (n = 41) were grouped into scales using factor analysis, and then refined to form the Multiple Sclerosis Impact Scale (MSIS-29), an instrument measuring the physical (20 items) and psychological (nine items) impact of multiple sclerosis. Five psychometric properties of the MSIS-29 (data quality, scaling assumptions, acceptability, reliability and validity) were examined in a separate postal survey of 1250 Multiple Sclerosis Society members. A preliminary responsiveness study of the MSIS-29 was undertaken in 55 people admitted for rehabilitation and intravenous steroid treatment of relapses. The MSIS-29 satisfied all psychometric criteria. Data quality was excellent, missing data were low (maximum 3.9%), item test-re-test reliability was high (r = 0.65-0.90) and scale scores could be generated for >98% of respondents. Item descriptive statistics, item convergent and discriminant validity, and factor analysis indicated that it was legitimate to generate scores for MSIS-29 scales by summing items. MSIS-29 scales showed good variability, small floor and ceiling effects, high internal consistency (Cronbach's alpha
                Bookmark

                Author and article information

                Journal
                Patient Prefer Adherence
                Patient Prefer Adherence
                ppa
                ppa
                Patient preference and adherence
                Dove
                1177-889X
                12 April 2021
                2021
                : 15
                : 713-719
                Affiliations
                [1 ]Clinical Neuroimmunology Unit and Multiple Sclerosis CSUR. Department of Neurology. Hospital Universitario “Virgen de la Arrixaca”, IMIB-Arrixaca , Murcia, Spain
                [2 ]Medical Department, Roche Farma , Madrid, Spain
                [3 ]Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe , Valencia, Spain
                [4 ]Department of Neurology, Hospital Universitario Puerta del Mar , Cádiz, Spain
                [5 ]Department of Neurology, Hospital Clínic i Provincial de Barcelona , Barcelona, Spain
                [6 ]Department of Neurology, Hospital Universitari Son Espases , Palma de Mallorca, Spain
                [7 ]Department of Neurology, Hospital Universitario Gregorio Marañón , Madrid, Spain
                [8 ]Department of Neurology, Hospital Universitario Álvaro Cunqueiro , Vigo, Spain
                [9 ]Department of Neurology, Hospital Universitario Cruces , Bilbao, Spain
                [10 ]Department of Neurology, Hospital Universitari de Bellvitge , Barcelona, Spain
                [11 ]Department of Neurology, Hospital General Universitario de Alicante , Alicante, Spain
                [12 ]Department of Neurology, Hospital Universitario La Princesa , Madrid, Spain
                [13 ]Department of Neurology, Hospital de la Santa Creu i Sant Pau , Barcelona, Spain
                [14 ]Department of Neurology, Hospital Universitario Ramón y Cajal , Madrid, Spain
                [15 ]Department of Statistics, IQVIA , Barcelona, Spain
                Author notes
                Correspondence: Jorge Maurino Roche Farma , Ribera Del Loira, 50, Madrid, 28042, SpainTel +34 913 24 81 00 Email jorge.maurino@roche.com
                Author information
                http://orcid.org/0000-0003-3767-3738
                http://orcid.org/0000-0003-0256-6748
                http://orcid.org/0000-0002-9897-0771
                http://orcid.org/0000-0003-0383-0256
                http://orcid.org/0000-0001-7976-5695
                http://orcid.org/0000-0001-9858-3555
                Article
                305707
                10.2147/PPA.S305707
                8052114
                33880015
                bb0e5fc1-1679-4cab-8093-72a5a6d649c4
                © 2021 Meca-Lallana et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 07 February 2021
                : 30 March 2021
                Page count
                Figures: 0, Tables: 7, References: 37, Pages: 7
                Funding
                Funded by: Medical Department of Roche Farma Spain;
                This study was funded by the Medical Department of Roche Farma Spain (ML41397).
                Categories
                Original Research

                Medicine
                neuromyelitis optica spectrum disorder,stigma,quality of life,depression,patient-reported outcomes

                Comments

                Comment on this article